Free Trial
→ One page of the SpaceX S-1 will move this stock overnight (From Behind the Markets) (Ad)tc pixel
OTCMKTS:CHGCY

Chugai Pharmaceutical Q3 2025 Earnings Report

Chugai Pharmaceutical logo
$22.79 -0.71 (-3.02%)
As of 06/9/2026 04:00 PM Eastern
ProfileEarnings HistoryForecast

Chugai Pharmaceutical EPS Results

Actual EPS
$0.23
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Chugai Pharmaceutical Revenue Results

Actual Revenue
$2.26 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Chugai Pharmaceutical Announcement Details

Quarter
Q3 2025
Date
10/24/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Chugai Pharmaceutical's next earnings date is estimated for Thursday, July 23, 2026, based on past reporting schedules.

Conference Call Resources

Chugai Pharmaceutical Earnings Headlines

Universe Pharmaceuticals (NASDAQ:UPC) & Chugai Pharmaceutical (OTCMKTS:CHGCY) Critical Analysis
June 9 at 3:49 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30828560
Chugai Pharmaceutical Co., Ltd. (CHGCY) Q4 2025 Earnings Call Transcript
January 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4863778-chugai-pharmaceutical-co-ltd-chgcy-q4-2025-earnings-call-transcript
Musk is burning $2.5 billion a quarter on AI. One company holds the key.
SpaceX's S-1 filing reveals $7.7 billion spent on AI infrastructure in a single quarter - not chips, not software, but power infrastructure. The filing shows $23.85 billion in servers and $14 billion in construction in progress, all dependent on one company's hardware. Without this supplier, Colossus doesn't run and the $1.25 billion Anthropic pays monthly stops flowing. The stock is still trading like no one has read the filing - but analyst Dylan Jovine has, and he's releasing the name at no cost.tc pixel
 |  Behind the Markets (Ad)
Chugai Reports Positive Data From TEIEN Study Of Port Delivery System With Ranibizumab In NAMD & DME
November 25, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-11/67067501-chugai-reports-positive-data-from-teien-study-of-port-delivery-system-with-ranibizumab-in-namd-dme-020.htm
Chugai Pharmaceutical to Merge with Renalys Pharma to Boost Kidney Disease Drug Development
November 18, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/chugai-pharmaceutical-to-merge-with-renalys-pharma-to-boost-kidney-disease-drug-development/ar-AA1QF83C
Rani Therapeutics Shares Double After Deal With Chugai Pharma
October 17, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/rani-therapeutics-shares-double-after-deal-with-chugai-pharma-ec8486c7
See More Chugai Pharmaceutical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Chugai Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chugai Pharmaceutical and other key companies, straight to your email.

About Chugai Pharmaceutical

Chugai Pharmaceutical (OTCMKTS:CHGCY) Co., Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics. One of its best-known products is tocilizumab (marketed in many territories through collaborative arrangements), reflecting the company’s capabilities in immunology and antibody engineering. Chugai’s product portfolio and pipeline include both in-house assets and programs developed in collaboration with external partners, demonstrating a mix of internal R&D and strategic alliances to advance new medicines.

Chugai maintains a long-standing strategic partnership with the Roche Group and operates primarily in the Japanese market while leveraging global commercialization channels through alliances. The company supports clinical development and manufacturing activities in Japan and engages with international partners to expand the reach of its therapies. Chugai is managed by a professional leadership and scientific team with experience in pharmaceutical R&D and commercial operations, and it positions itself as a research-oriented company within the global biopharmaceutical landscape.

View Chugai Pharmaceutical Profile
Earnings Tools